This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Wall Street Analysts Believe FuelCell Energy (FCEL) Could Rally 39.58%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 39.6% upside potential for FuelCell Energy (FCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FCELNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GKOSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 26.78% Upside in Byrna Technologies (BYRN): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 26.8% upside potential for Byrna Technologies (BYRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BYRNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Copa Holdings (CPA) Could Surge 42.18%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 42.2% upside potential for Copa Holdings (CPA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CPANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 25.9% Upside in Veris (VRE): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.9% in Veris (VRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VRENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Quanex (NX) Could Rally 83.26%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 83.3% in Quanex (NX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Manchester United (MANU) Have the Potential to Rally 29.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Manchester United (MANU) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MANUNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think MongoDB (MDB) Could Surge 31.85%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for MongoDB (MDB) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MDBNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MNPRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Perrigo (PRGO) Have the Potential to Rally 32.86% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 32.9% upside potential for Perrigo (PRGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRGONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe West Pharmaceutical (WST) Could Rally 26.92%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Sangoma Technologies Corporation (SANG)? Wall Street Analysts Think 47.2%
by Zacks Equity Research
The mean of analysts' price targets for Sangoma Technologies Corporation (SANG) points to a 47.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SANGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does QuinStreet (QNST) Have the Potential to Rally 76.84% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for QuinStreet (QNST) points to a 76.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
QNSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think The RealReal (REAL) Could Surge 76.88%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in The RealReal (REAL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
REALNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe ZipRecruiter (ZIP) Could Rally 28%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for ZipRecruiter (ZIP) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZIPNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SGMTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 25.35% Upside in HubSpot (HUBS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in HubSpot (HUBS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HUBSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VIGLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PHATPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ALVONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APGEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Concentra (CON) Could Rally 27.1%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Concentra (CON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CONNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 46.32% Upside in BILL Holdings (BILL): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46.3% in BILL Holdings (BILL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BILLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Birkenstock (BIRK) Could Rally 25.79%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Birkenstock (BIRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BIRKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GLUENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate